Varda Space Industries
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries announced $251M in Series D financing on September 30, 2026. Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Round details
The financing includes backing from Lux Capital, Natural Capital, Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step. The company did not publish a valuation with the announcement.
- Round: Series D
- Capital announced: $251M
- Total funding reported: $598M
- Headquarters: El Segundo, CA
How the company plans to use the capital
Varda said the round gives it the resources to increase its cadence, deepen its pharmaceutical partnerships, and get closer to delivering the first medicine made in space.
Why this matters for GTM teams
Since its first mission launched in 2023, Varda has completed six successful reentry missions, with more than a dozen further launches and reentries planned through 2028, according to the announcement.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Varda Series D announcement.
Company Info
Investors (8)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started